T-cell therapy + rituximab + aldesleukin

This is a combination immunotherapy regimen consisting of three components: - **T-cell therapy** (such as adoptive cell transfer, including tumor-infiltrating lymphocytes or engineered T cells), which involves the infusion of autologous or allogeneic T cells to target and destroy cancer cells. The mechanism relies on direct cytotoxicity against tumor antigens and immune modulation[4]. - **Rituximab**, a chimeric monoclonal antibody targeting CD20 on B lymphocytes, leading to B cell depletion via mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and direct apoptosis[5]. - **Aldesleukin** (recombinant interleukin-2), a cytokine that stimulates proliferation and activation of T cells and natural killer (NK) cells, enhancing immune responses against tumors[6][8][10]. The rationale for combining these agents is to leverage the direct anti-tumor activity of adoptively transferred T-cells, enhance their expansion/activation with aldesleukin, and deplete malignant B-cells with rituximab. Aldesleukin may also potentiate ADCC by expanding Fc receptor-bearing effector populations in vivo when used with rituximab[1]. This combination has been explored primarily in hematologic malignancies such as non-Hodgkin lymphoma but may be considered investigational for other cancers.

Other names

ACTR T cells + rituximab + aldesleukinACTR T cells + rituximab + IL-2CD16V-41BB-CD3zeta engineered T cells + rituximab + aldesleukin